Evidence method
Level · gp.fundamentals.debt_to_revenue
642.45% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Dec 31, 2022
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-008927General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
13.71% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-3357.30% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-91.67% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-4274.31% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
3098.08% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
762.58% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 13235.29%
- Current
- 642.45%
- Delta
- -12592.84%
- Previous
- 114.71%
- Current
- 13.71%
- Delta
- -100.99%
- Previous
- -10104.41%
- Current
- -3357.30%
- Delta
- 6747.12%
- Previous
- -97.16%
- Current
- -91.67%
- Delta
- 5.49%
- Previous
- -16222.06%
- Current
- -4274.31%
- Delta
- 11947.75%
- Previous
- 11133.82%
- Current
- 3098.08%
- Delta
- -8035.75%
- Previous
- 3035.29%
- Current
- 762.58%
- Delta
- -2272.71%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Analogous To · CUE state analogue 4 →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · CUE CAPEX_INTENSITY_DECREASED →Transitioned To · CUE CASH_GENERATION_INCREASED →Transitioned To · CUE GROWTH_INCREASED →Transitioned To · CUE PROFITABILITY_INCREASED →Transitioned To · CUE R_AND_D_INTENSITY_DECREASED →Transitioned To · CUE SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.